<DOC>
	<DOCNO>NCT02006225</DOCNO>
	<brief_summary>Plerixafor intensively use recent year harvest autologous stem cell lymphoma myeloma adult patient . Its use indicated failure harvest GCSF alone . Nevertheless , pediatric population appliance less well establish indication less well confirm .Several disease state diagnosis may prompt anticipation difficulty harvest stem cell use GCSF . Such patient may benefit utilize plerixafor first-line rather exhaust stem cell niche GCSF alone go plerixafor second-line rescue procedure . In study propose examine applicability feasibility harvest autologous stem cell mean GCSF + plerixafor first-line measure pediatric patient specific indication .</brief_summary>
	<brief_title>Stem Cell Harvesting Using GCSF Plus Plerxiafor , First -Line , Heavily Pre- Treated Pediatric Oncology Patients .</brief_title>
	<detailed_description>Improve report outcomes child undergo peripheral stem progenitor cell harvest apply plerixafor first-line aphaeresis , include : Pre-harvesting FACS-derived CD34+ cell number . Number stem cell harvest . Number T-cells harvest . Days hospitalization . Procedure related toxicity include : Infections . Line complication . Other organ toxicity . Compare outcomes plerixafor-derived stem progenitor cell harvest different pediatric oncological disease , include high-risk neuroblastoma , high-risk brain tumor , high-risk sarcoma relapse lymphoma . Outcomes analyzed : 1 . Peripheral blood stem cell content mean percentage CD34+ cell , condition protocol ( 4 day 10mcg/kg GCSF per day one dose plerixafor 0.24mg/kg 10 hour collection ) harvesting . 2 . Number stem cell harvest . 3 . Morbidity : 1 . Bleeding time catheter placement , harvest procedure post harvesting . 2 . Infections : localize vs. generalize . Type pathogen isolate . 4 . Platelet number hemoglobin level post harvesting . 5. kidney function . 6 . Duration hospitalization : Evaluation time course day hospitalization harvest day discharge .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>The following patient include study : Patients highrisk neuroblastoma thirdline chemotherapy . Patients highrisk medulloblastoma/PNET spinal irradiation . Patients primary sarcomas third line therapy , Patients relapse lymphomas third line chemotherapy . Patients relapse neuroblastoma , medulloblastoma , lymphoma sarcoma previous autologous stem cell transplantation . Age equal less 30 year time diagnosis . Patients eligible AHCT accord treat protocol patient neuroblastoma eligible 131IMIBGtherapy . Patients maligancies disease candidate autologous stem cell transplantation , take autologus stem cell back . Healthy stem cell donor Patients old 30 year Patients non maligancies disease candidate autologous stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>autologous</keyword>
	<keyword>stem cell</keyword>
	<keyword>transplantation</keyword>
</DOC>